Aptar acquires Nanopharm and Gateway Analytical to speed up drug development

Aptar Pharma has acquired two leading analytical services as part of a strategy to broaden its portfolio and help accelerate and derisk complex product developments.

Nanopharm and Gateway Analytical, which were acquired for approximately $50 million, will expand Aptar Pharma’s services platform through value-added and differentiated, testing and development services for all stages of drug development and commercialisation. This will enable Aptar Pharma to collaborate earlier with customers to support complex drug formulations and delivery requirements.

Nanopharm founder and chief scientific officer, professor Robert Price said: “In Aptar we have found the ideal partner to continue the successful growth of Nanopharm. Aptar Group is perfectly positioned to support the development of our science driven, solution-oriented services for inhalation and nasal drug products. This exciting new chapter in our development will allow us to deliver yet more as we leverage Aptar’s expertise and infrastructure to better serve our highly-valued clients.”

“We are delighted to join Aptar Pharma, a leader in the field of drug delivery devices and value-added services to their pharmaceutical customers,” adds David Exline, President of Gateway Analytical. “With our combined resources and teams we can offer customers a broader range of specialised and differentiated products and services, and maintain the superior level of service and quality they’ve been receiving from Gateway Analytical. In addition, our worldwide reach will be significantly enhanced with the leadership of Aptar Pharma.”

Stephan Tanda, president and CEO, said: “These strategic investments further strengthen our best in class Pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our service offerings. The expertise of two established leaders, Nanopharm, a leader in inhalation and nasal drug development services, and Gateway, a leader in particulate detection and analysis for the injectables market, are complementary to our existing laboratory and analytical services and will bring additional value to our customers as they navigate the challenging regulatory landscape and seek to bring their products to market faster.”